Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046878 | 0.84 | ROCK2 (0.56) | ROCK2ROCK1IMPDH2HDAC1HDAC8 | |
| SCHEMBL3049111 | 0.84 | ROCK2 (0.51) | ROCK2ROCK1IMPDH2EGFRADAMTS4 | |
| SCHEMBL3042553 | 0.81 | ROCK2 (0.48) | ROCK2ROCK1IMPDH2EGFRADAMTS4 | |
| SCHEMBL3039175 | 0.81 | ROCK2 (0.47) | ROCK2ROCK1IMPDH2EGFRHDAC8 | |
| SCHEMBL3840595 | 0.78 | KDM4E (0.49) | ROCK2ROCK1IMPDH2ADAMTS4ADAMTS5 | |
| SCHEMBL3048705 | 0.77 | GPR132 (0.51) | ROCK2ROCK1IMPDH2SMPD1HTT | |
| SCHEMBL3837692 | 0.75 | ROCK2 (0.49) | ROCK2ROCK1IMPDH2ADAMTS4ADAMTS5 | |
| SCHEMBL3039346 | 0.69 | ROCK2 (0.57) | ROCK2ROCK1IMPDH2HTT | |
| SCHEMBL94229 | 0.68 | IMPDH2 (0.52) | ROCK2ROCK1IMPDH2ADAMTS4ADAMTS5 | |
| SCHEMBL3039120 | 0.68 | POLB (0.58) | ROCK2ROCK1IMPDH2ADAMTS4ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | ROCK2 2207/4885ROCK1 1831/4885IMPDH2 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.